Prof Petrylak talks with ecancer at the Best of ASCO 2017 meeting in Miami about the early use of the CYP17A1 inhibitor, abiraterone, for patients with metastatic, hormone sensitive, prostate cancer. He goes on to discuss the data from, and the...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2uhE9Jc
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2oYRz8x via IFTTT
-
© 2011 IRA/NCTE. All rights reserved. materials may be reproduced for educational purposes. Book Review Template Let's explore some prop...
-
by Fangzhou Li, Zhiming Feng, Peng Li, Zhen You The study of urban spatial interaction is closely linked to that of economic geography, urb...
-
Abstract Background Individuals with advanced, incurable cancer often experience high physical and psychological symptom burden. Family an...
-
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor British Journal of Canc...
-
Class-switch recombination (CSR) alters the Ig isotype to diversify antibody effector functions. IgD CSR is a rare event, and its regulation...
-
ACS Nano DOI: 10.1021/acsnano.6b06114 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kOsUGq via...
-
Abstract RNA degradation is a major problem in tissue banking. We explored the effect of thawing flash-frozen biospecimens on the quality a...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2juls25 via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου